RAS mutations are detected in about 50% of CRC patients; KRAS mutations are found in about 40% of cases, NRAS mutations are found in about 3-5% of cases, and HRAS mutations are negligible events [33, 34]. Here, KRAS is linked to colorectal carcinoma.